Evidence map›Paper›PMID 28866852›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2017

Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).

M Celli, P D'Eufemia, P Persiani, A Turchetti, A Febbo, Y D'Alfonso, L Celli, A Zambrano

Open access · greenAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Management of primary and secondary osteoporosis in children.Therapeutic advances in musculoskeletal disease · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M CelliDepartment of Pediatrics, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy. m.celli@policlinicoumberto1.it.ORCID 0000-0002-0751-2688
P D'EufemiaDepartment of Pediatrics, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy.
P PersianiDepartment of Anatomic Histologic Forensic and Locomotor Apparatus Sciences, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy.
A TurchettiDepartment of Pediatrics, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy.
A FebboDepartment of Pediatrics, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy.
Y D'AlfonsoDepartment of Pediatrics, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy.
L CelliDepartment of Pediatrics, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy.
A ZambranoDepartment of Pediatrics, "Sapienza" University of Rome, Viale Regina Elena, 324, 00324, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive syndrome characterized by juvenile-onset osteoporosis and ocular abnormalities due to a low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation. Treatment with bisphosphonates, particularly with pamidronate and risedronate, has been reported to be of some efficacy in this condition. We report on a patient with OPPG due to an LRP5 gene mutation, who showed an encouraging response after a 36-month period of neridronate therapy. We report a case of a patient treated with bisphosphonates. Bisphosphonates should be administered in OPPG patients as a first-line therapy during early childhood.

Indexed as

AdolescentBone Density Conservation AgentsDiphosphonatesHumansLow Density Lipoprotein Receptor-Related Protein-5MaleMutationOsteogenesis ImperfectaOsteoporotic FracturesRadiographySpinal Fractures6-amino-1-hydroxyhexane-1,1-diphosphonateBone Density Conservation AgentsDiphosphonatesLow Density Lipoprotein Receptor-Related Protein-5LRP5 protein, humanBisphosphonateBoneLRP5OPPGOsteoporosis-pseudogliomaOsteoporosis-pseudoglioma syndrome

Identifiers

PMID28866852
OpenAlexW2752693522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.